Zavegepant

Last updated

Zavegepant
Zavegepant.svg
Clinical data
Trade names Zavzpret
Other namesBHV-3500
License data
Routes of
administration 		Nasal
Drug class Calcitonin gene-related peptide receptor antagonist
ATC code
Legal status
Legal status
Identifiers
  • N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C36H46N8O3
Molar mass 638.817 g·mol−1
3D model (JSmol)
  • CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O
  • InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1
  • Key:JJVAPHYEOZSKJZ-JGCGQSQUSA-N
  • Key:VQDUWCSSPSOSNA-RYWNGCACSA-N

Zavegepant, sold under the brand name Zavzpret, is a medication used for the treatment of migraine. [1] Zavegepant is a calcitonin gene-related peptide receptor antagonist. [1] It is sprayed into the nose. [1] It is sold by Pfizer. [1]

Contents

The most common adverse reactions include taste disorders, nausea, nasal discomfort, and vomiting. [1]

Zavegepant was approved for medical use in the United States in March 2023. [1] [2] [3] [4]

Medical uses

Zavegepant is indicated for the acute treatment of migraine with or without aura in adults. [1] [5] [6]

References

  1. 1 2 3 4 5 6 7 8 "Zavzpret- zavegepant spray". DailyMed. 9 March 2023. Retrieved 25 August 2023.
  2. ↑ "Drug Approval Package: Zavzpret". U.S. Food and Drug Administration (FDA). 3 April 2023. Archived from the original on 25 August 2023. Retrieved 25 August 2023.
  3. ↑ "Pfizer's Zavzpret (Zavegepant) Migraine Nasal Spray Receives FDA Approval" (Press release). 10 March 2023.
  4. ↑ Dhillon S (June 2023). "Zavegepant: First Approval". Drugs. 83 (9): 825–831. doi:10.1007/s40265-023-01885-6. PMC   10209931 . PMID   37227596.
  5. ↑ Khan ZZ, Ahmed U, Shahzad F, Ali M, Tousif K, Ahmed U, et al. (July 2023). "Safety and Efficacy of Zavegepant in Treating Migraine: A Systematic Review". Cureus. 15 (7): e41991. doi: 10.7759/cureus.41991 . PMC   10428082 . PMID   37593294.
  6. ↑ Martirosov AL, Giuliano C, Shupp M, Channey S, Kale-Pradhan PB (October 2023). "Zavegepant Intranasal Spray for Migraines". The Annals of Pharmacotherapy. 58 (8): 827–833. doi:10.1177/10600280231209439. PMID   37897226. S2CID   264543368.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.